Min J. Shin
Yangsan, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
MHY5535, a novel PPARα antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 19, 2026
Role of Peroxisome Proliferator-Activated Receptor α-Dependent Mitochondrial Metabolism in Ovarian Cancer Stem Cells.
Journal: International journal of molecular sciences
Published: September 28, 2024
Identification of CD109 in the extracellular vesicles derived from ovarian cancer stem-like cells.
Journal: BMB reports
Published: January 15, 2024
Injectable composite hydrogels embedded with gallium-based liquid metal particles for solid breast cancer treatment via chemo-photothermal combination.
Journal: Acta biomaterialia
Published: December 22, 2023
BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
Journal: Anticancer research
Published: September 22, 2023
CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Journal: International journal of molecular sciences
Published: March 28, 2023
TRIB2 Stimulates Cancer Stem-Like Properties through Activating the AKT-GSK3β-β-Catenin Signaling Axis.
Journal: Molecules and cells
Published: February 03, 2021
CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells.
Journal: BMB reports
Published: May 13, 2020
Expression Level of Prostaglandin D2 Receptor 2 Regulates Hair Regression.
Journal: The Journal of investigative dermatology
Published: September 16, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026